Nothing Depressing Cyberonics

By far, the big percentage gainer today was Cyberonics (Nasdaq: CYBX). With its stock up almost 70% on the day, the company is basking in the afterglow of a 5-to-2 FDA advisory panel vote recommending approval of its implantable device for treating depression.

Essentially, the company's VNS Therapy System, which can be administered during a one-hour outpatient surgery, involves an implantable medical device consisting of a pacemaker-like generator and a nerve-stimulation electrode that delivers mild electrical signals to the vagus nerve in the left side of the neck. If approved, it will be the first long-term treatment for patients with treatment-resistant depression (TRD).

Four million Americans suffer specifically from TRD. These people are often isolated, hopeless, desperate, and unemployed. They are frequent visitors to emergency rooms and hospitals, and studies show that annual health-care costs for patients with TRD exceed $40,000 per patient. That is a big market where treatment costs are clearly very high.

Getting FDA approval may nonetheless be tough. According to a Reuter's report, there were a number of "data problems," but the need to help these patients carried the day. It helps, certainly, that the device is already approved by the FDA to treat epilepsy.

What might surprise you is that the TRD market is believed to be at least 10 times that of the epilepsy market. If so, Cyberonics has a $1 billion device on its hands. The stock, meanwhile, trades at 23 times estimated 2005 earnings. Although not cheap, it does not reflect the potentially explosive long-term sales growth for VNS Therapy.

Among those cheering today's news is Boston Scientific (NYSE: BSX) -- owner of 3.3 million Cyberonics shares. Shareholders can't help but be pleased, but with 835 million Boston Scientific shares outstanding, the good news barely trickles down to the typical Boston Scientific investor.

Spend time talking to other investors about Cyberonics or Boston Scientific on The Motley Fool discussion boards.

Fool contributor W.D. Crotty is only depressed he owns Boston Scientific (which is hardly depressing) instead of Cyberonics.

Comment (0)
Recommended (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 508486, ~/articles/articlehandler.aspx, 8/30/2008 12:06:53 PM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Related Tickers

Boston Scientific Corp.

BSX Down! $12.56 -0.28 (-2.18%) 4:01 PM
CAPS Rating:
471 Outperforms
104 Underperforms
Rate This Stock

Major Indices

S&P 5001,282.83 -1.37%
DJIA11,543.55 -1.47%
RSL 2K739.50 -1.11%
NASD2,367.52 -1.83%
Updated: 5:10:01 PM
Sponsored by:

The Motley Poll

Where will the U.S. dollar go from here?

Sponsored by: